245 related articles for article (PubMed ID: 21215696)
41. A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent.
Arima M; Matsuda A; Nitta M; Yoshida K; Shimizu M
Heart Vessels; 2012 Jan; 27(1):106-9. PubMed ID: 21445598
[TBL] [Abstract][Full Text] [Related]
42. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
Price MJ; Murray SS; Angiolillo DJ; Lillie E; Smith EN; Tisch RL; Schork NJ; Teirstein PS; Topol EJ;
J Am Coll Cardiol; 2012 May; 59(22):1928-37. PubMed ID: 22624833
[TBL] [Abstract][Full Text] [Related]
43. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
[TBL] [Abstract][Full Text] [Related]
44. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
Carlquist JF; Knight S; Horne BD; Huntinghouse JA; Rollo JS; Muhlestein JB; May H; Anderson JL
Thromb Haemost; 2013 Apr; 109(4):744-54. PubMed ID: 23364775
[TBL] [Abstract][Full Text] [Related]
45. The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy.
Tatarunas V; Jankauskiene L; Kupstyte N; Skipskis V; Gustiene O; Grybauskas P; Lesauskaite V
Blood Coagul Fibrinolysis; 2014 Jun; 25(4):369-74. PubMed ID: 24418943
[TBL] [Abstract][Full Text] [Related]
46. CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.
Bergmeijer TO; Janssen PW; Schipper JC; Qaderdan K; Ishak M; Ruitenbeek RS; Asselbergs FW; van 't Hof AW; Dewilde WJ; Spanó F; Herrman JP; Kelder JC; Postma MJ; de Boer A; Deneer VH; ten Berg JM
Am Heart J; 2014 Jul; 168(1):16-22.e1. PubMed ID: 24952855
[TBL] [Abstract][Full Text] [Related]
47. Can we override clopidogrel resistance?
Pena A; Collet JP; Hulot JS; Silvain J; Barthélémy O; Beygui F; Funck-Brentano C; Montalescot G
Circulation; 2009 Jun; 119(21):2854-7. PubMed ID: 19487603
[No Abstract] [Full Text] [Related]
48. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.
Jin B; Ni HC; Shen W; Li J; Shi HM; Li Y
Mol Biol Rep; 2011 Mar; 38(3):1697-702. PubMed ID: 20845077
[TBL] [Abstract][Full Text] [Related]
49. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
[TBL] [Abstract][Full Text] [Related]
50. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
Sawada T; Shinke T; Shite J; Honjo T; Haraguchi Y; Nishio R; Shinohara M; Toh R; Ishida T; Kawamori H; Kozuki A; Inoue T; Hariki H; Hirata K
Circ J; 2011; 75(1):99-105. PubMed ID: 21099121
[TBL] [Abstract][Full Text] [Related]
51. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Buonamici P; Antoniucci D; Abbate R; Gensini GF
Am J Cardiol; 2009 Mar; 103(6):806-11. PubMed ID: 19268736
[TBL] [Abstract][Full Text] [Related]
52. Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism.
Gajos G; Zalewski J; Nessler J; Zmudka K; Undas A; Piwowarska W
Kardiol Pol; 2012; 70(5):439-45. PubMed ID: 22623230
[TBL] [Abstract][Full Text] [Related]
53. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
Tiroch KA; Sibbing D; Koch W; Roosen-Runge T; Mehilli J; Schömig A; Kastrati A
Am Heart J; 2010 Sep; 160(3):506-12. PubMed ID: 20826260
[TBL] [Abstract][Full Text] [Related]
54. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
[TBL] [Abstract][Full Text] [Related]
55. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
56. Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology.
Li P; Cao M; Liu L; Chen L; Liang S; Wang Y
BMC Pharmacol Toxicol; 2024 Jun; 25(1):34. PubMed ID: 38845014
[TBL] [Abstract][Full Text] [Related]
57. Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in japanese patients receiving clopidogrel.
Nishio R; Shinke T; Otake H; Sawada T; Haraguchi Y; Shinohara M; Toh R; Ishida T; Nakagawa M; Nagoshi R; Kozuki A; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Shite J; Hirata K
Circ J; 2012; 76(10):2348-55. PubMed ID: 22785462
[TBL] [Abstract][Full Text] [Related]
58. Genetic causes of clopidogrel nonresponsiveness: which ones really count?
Momary KM; Dorsch MP; Bates ER
Pharmacotherapy; 2010 Mar; 30(3):265-74. PubMed ID: 20180610
[TBL] [Abstract][Full Text] [Related]
59. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
Verschuren JJ; Boden H; Wessels JA; van der Hoeven BL; Trompet S; Heijmans BT; Putter H; Guchelaar HJ; Schalij MJ; Jukema JW
Int J Cardiol; 2013 Sep; 167(6):2882-8. PubMed ID: 22940005
[TBL] [Abstract][Full Text] [Related]
60. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
